Collectively, these findings support that stroma-derived ASPN mediates paracrine activation of HER2/HER3 in metastatic prostate cancer while a subset of cancers may have additional autocrine or paracrine activation of HER2/HER3 signaling through NRG1. Here, ERBB2 is linked to metastatic prostate carcinoma.